Information Provided By: 
Fly News Breaks for March 2, 2017
AKRX
Mar 2, 2017 | 06:27 EDT
Piper Jaffray analyst David Amsellem says that while Akorn's 2017 outlook reflects pressure on injectable ephedrine and earnings even with contribution from new launches factored into the ranges, the company is positioned for "significant" earnings recovery and long-term growth beyond this year. The analyst highlights the depth of Akorn's generics pipeline and its focus on more complex dosage forms. He lowered his price target for the shares to $29 from $35 and keeps an Overweight rating on the name.
News For AKRX From the Last 2 Days
There are no results for your query AKRX
